Cheap gout drug colchicine added to UK’s RECOVERY COVID-19 trialColchicine, a cheap and readily available anti-inflammatory drug used to treat diseases such as gout, is to be Share XCheap gout drug colchicine added to UK’s RECOVERY COVID-19 trialhttps://pharmaphorum.com/news/colchicine-added-to-uks-ground-breaking-recovery-covid-19-trial/
EU fines Teva and Cephalon €60.5m for ‘pay for delay’ schemeThe European Union has fined Teva and its neurology unit Cephalon €60.5 million for an elaborate “pay for Share XEU fines Teva and Cephalon €60.5m for ‘pay for delay’ schemehttps://pharmaphorum.com/news/eu-fines-teva-and-cephalon-e60-5m-for-pay-for-delay-scheme/
Concerns emerge after AZ’s lucky vaccine trial ‘mistake’AstraZeneca may have tried a positive spin on the trial mistake that led to the accidental discovery of Share XConcerns emerge after AZ’s lucky vaccine trial ‘mistake’https://pharmaphorum.com/news/concerns-emerge-after-azs-vaccine/
Novartis set to overcome $14 billion patent cliff say analystsNovartis’ pipeline is strong enough to overcome a $14 billion patent cliff as blockbuster drugs face generic competition Share XNovartis set to overcome $14 billion patent cliff say analystshttps://pharmaphorum.com/news/novartis-set-to-overcome-14-billion-patent-cliff-analyst/
GE Healthcare’s AI tool helps clinicians intubate patients accurately and safelyAn artificial intelligence tool developed by GE Healthcare twinned with a mobile X-ray device can help the placement Share XGE Healthcare’s AI tool helps clinicians intubate patients accurately and safelyhttps://pharmaphorum.com/news/ge-healthcares-ai-tool-helps-clinicians-intubate-patients-accurately-and-safely/
Pfizer/BioNTech prep US COVID-19 vaccine launch after emergency filingPfizer and BioNTech have filed for emergency use of their COVID-19 vaccine candidate in the US, paving the Share XPfizer/BioNTech prep US COVID-19 vaccine launch after emergency filinghttps://pharmaphorum.com/news/pfizer-biontech-us-covid-19-vaccine-launch-emergency-filing/
Bayer provides funding to five more digital health start-upsBayer has provided funding to five more digital health start-ups as part of its G4A partnering programme, which Share XBayer provides funding to five more digital health start-upshttps://pharmaphorum.com/news/bayer-provides-funding-to-five-more-digital-health-start-ups/
ViiV could challenge Gilead with long-acting HIV PrEP shotGlaxoSmithKline’s HIV joint venture ViiV Healthcare could mount a challenge to Gilead’s HIV pre-exposure prophylaxis (PrEP) medicines after Share XViiV could challenge Gilead with long-acting HIV PrEP shothttps://pharmaphorum.com/news/viiv-could-challenge-gilead-with-long-acting-hiv-prep-shot/
NICE backs Lilly’s Emgality for migraine, adding pressure on NovartisUK cost-effectiveness agency NICE has said that Eli Lilly’s Emgality can be made available through the NHS for Share XNICE backs Lilly’s Emgality for migraine, adding pressure on Novartishttps://pharmaphorum.com/news/nice-backs-lillys-emgality-for-migraine-adding-pressure-on-novartis-rival/
